Navigation Links
Researchers find possible new treatment strategies for pancreatic cancer

Athens, Ga. New University of Georgia research has identified a protein that can be modified to improve the effectiveness of one of the most common drugs used to treat pancreatic cancer.

The research, published in the March edition of the journal Cancer Research, found that a cell-surface protein called CNT1, which transports cancer-killing drugs into tumor cells, was reduced in function in two thirds of pancreatic tumors. By improving the function of CNT1, the researchers increased the effectiveness of the cancer-killing drugs in pancreatic tumor cells derived from human patients, said lead-author Raj Govindarajan, assistant professor of pharmaceutical and biomedical sciences in the UGA College of Pharmacy.

"The transporter was failing to take up the drug, so there were a bunch of different drug-resistant tumor cells," said Govindarajan. "Therapies that restore CNT1 could increase the effectiveness of the drug by helping carry the drug into the cell."

The drug most commonly used to treat pancreatic cancer is called gemcitabine and works by entering into the DNA of cancer cells and stopping replication. Many pancreatic tumor cells are resistant to gemcitabine, which makes the disease very difficult to treat, explained Govindarajan.

The researchers identified different methods to enhance CNT1 function and slow growth of the tumor cells. They found that by using additional drugs that inhibit pathways that degrade CNT1, they could partially restore its normal function and transport more gemcitabine into the tumor cells to prevent proliferation of the tumor.

The researchers attained the same results by genetically augmenting CNT1. "We over-expressed this protein in tumor cells so that it is functional continuously throughout the cell cycle, and it took up a lot of the drug and facilitated tumor killing," said Govindarajan. "So it shows potential for therapeutic aspects."

Govindarajan and his colleagues also found that CNT1 was likely regulated by tiny RNA molecules called micro-RNAs. "Micro-RNAs are clearly emerging as a new paradigm in gene regulation," said Govindarajan. "We could potentially use micro-RNAs to increase CNT1 expression and increase tumor-cell targeting of gemcitabine."

The American Cancer Society estimates that 43,000 people will be diagnosed with pancreatic cancer every year, and about 85 percent of those will die within one year of diagnosis.

Govindarajan said that the findings need to be evaluated in laboratory animals for both effectiveness and toxicity aspects to determine if they are feasible therapeutic options. He hopes that future studies will confirm the possibilities of combining additional therapies with gemcitabine to more effectively treat pancreatic cancer. "What we are trying to do is see if we can improve the standard of care for treating pancreatic cancer," he said.


Contact: Raj Govindarajan
University of Georgia

Related biology news :

1. Scripps oceanography researchers discover arctic blooms occurring earlier
2. Nature study: Jefferson researchers unravel proteins elusive role in embryo and disease development
3. York U researchers uncovering how ovarian cancer resists chemotherapy
4. Researchers predict age of T cells to improve cancer treatment
5. Researchers looking at a rare disease make breakthrough that could benefit everyone
6. Researchers develop curious snapshot of powerful retinal pigment and its partners
7. 20 researchers selected as 2011 Leopold Leadership Fellows
8. Researchers from Hebrew U., US discover how mercury gets into fish we eat
9. Canadian researchers first worldwide to generate pluripotent stem cells from horses
10. Researchers have found how brain cells control their movement to form the cerebral cortex
11. Cleveland Clinic researchers honored for contributions to science and technology
Post Your Comments:
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
Breaking Biology Technology: